News & updates

Belgian Policy Document Social Affairs and Healthcare

posted on November 17th 2015 by Ludwig Everaert
On 12 November 2015, the policy document on Social Affairs and Healthcare was presented by Minster Maggie De Block to the Belgian Chamber of Representatives. This policy document clarifies various issues that are relevant for the Pharmaceutical and Associated Industries.

Meet us at CPhI Madrid 2015

posted on September 30th 2015 by Ludwig Everaert
Archemin will attend the CPhI Worldwide in Madrid. This world's leading pharmaceutical networking event will be an excellent occasion to meet our delegates.

Price freeze for Medicinal Products in Belgium

posted on July 20th 2015 by Melissa Penninck
On 17 July 2015, the Belgian Ministerial Council decided to continue the price freeze for Medicinal Products. The decision has been taken to limit the healthcare expenditures. The prices for Medicinal Products are frozen since 2009; deviations are only possible if there is adequate justification.

eCTD format obligatory for Decentralised Procedure

posted on July 01st 2015 by Ingrid Nobels
From the 1st of July 2015 all new Marketing Authorisation Applications for medicinal products for the Decentralised Procedure (DCP) must be submitted in electronic Common Technical Document (eCTD) format. By 2017 the NeeS format will be phased out completely and the eCTD will be the only acceptable template.

Disclosure of transfers of value

posted on January 29th 2015 by Anonymous
Pursuant to Chapter 5bis of the Code of deontology, pharmaceutical companies shall disclose transfers of value they make, directly or indirectly, for the benefit of a healthcare professional ("HCP") or organisation ("HCO").

Hospitality towards healthcare professionals limited by Mdeon

posted on January 29th 2015 by Anonymous
The European medicines Directive and article 10 of the Belgian Medicines Law regulate advertising of medicinal products to healthcare professionals.

Selincro (nalmefene) reimbursed in Belgium

posted on March 25th 2014 by Ludwig Everaert
Class I reimbursement has been obtained for Selincro in Belgium. The product is expected to revolutionarize the treatment of alcoholism, a condition which affects millions of people. Selincro is original in the sense that the product can be taken as needed for the reduction of alcohol consumption in patients with alcohol dependence.

A 60% increase in sales tax on medical devices in Belgium

posted on January 01st 2014 by Ludwig Everaert
From 1 January 2014 on, the tax on the turnover of medical devices increases from 0.18417 to 0.29438%; this is an increase of nearly 60% (law of  15 December 2013, published in the Belgian State Gazette of 20 December 2013).

Pharmaceuticals in the environment… moving towards ecopharmacovigilance

posted on December 26th 2013 by Ingrid Nobels
The monitoring of chemicals in the aquatic environment is in Europe regulated by the water framework directive (WFD).  Agreement has been reached in Europe on an updated list of priority substances considered to present a risk to the aquatic environment.

Archemin Delegation present at ISPOR 2013

posted on November 06th 2013 by Inneke Van de Vijver
Whereas the development of medicinal products used to be a purely sequential process, consisting of clinical development, registration process followed by a price and reimbursement application and then market launch, this is no longer realistic.